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intradialytic weight loss as well as Kt/V did not differ betweenBlood volume controlled hemodialysis in hypotension-prone
the two treatments.patients: A randomized, multicenter controlled trial.
Conclusions. An overall improvement in the treatment tol-Background. Recently we have devised and tested a biofeed-
erance was observed with BVT, particularly intradialytic car-back system for controlling blood volume (BV) changes during
diovascular stability. Patients with the highest incidence of IDHhemodialysis (HD) along an ideal trajectory (blood volume
tracking, BVT), continuously modifying the weight loss rate and during conventional HD and free from chronic pre-dialysis hypo-
dialysate conductivity. This multicenter, prospective, random- tension seem to respond better. Inter-dialysis symptoms also
ized, crossover study aimed to clarify whether BVT (treat- seem to improve with control of BV.
ment B) can improve hypotension-prone patients’ treatment tol-
erance, compared with conventional hemodialysis (treatment A).
Methods. Thirty-six hypotension-prone patients enrolled from
Symptomatic intradialytic hypotension affects twenty10 hemodialysis (HD) centers were randomly assigned to ei-
ther of the study sequences ABAB or BABA, each lasting to 50% of end-stage renal disease (ESRD) patients dur-
four months. ing their regular dialysis therapies [1, 2]. Hypotension epi-
Results. A 30% reduction in intradialytic hypotension (IDH) sodes are frequently complicated by symptoms of dizzi-events was observed in treatment B as compared with A (23.5%
ness, weakness, nausea, cramps, blurred vision and fatiguevs. 33.5%, P 0.004). The reduction was related to the number
occurring during the blood pressure falls and often per-of IDH in treatment A (y  0.54x  5; r  0.4; P  0.001): the
more IDH episodes in treatment A, the better the response sisting after the hemodialysis (HD) session. As a result,
in treatment B. The best responders to treatment B showed intradialytic hypotension (IDH) greatly contributes to
pre-dialysis systolic blood pressure values higher than the poor
overall patient morbidity and not only limits fluid re-responders (P 0.04). A 10% overall reduction in inter-dialysis
moval during a dialysis session, but also increases thesymptoms was obtained also in treatment B compared to A
(P  0.001). Body weight gain, pre-dialysis blood pressure, need for nursing intervention.
Dialysis-induced hypotension and its related symp-
toms can be traced back to two main mechanisms inter-
1 Other participants (institutions) include: Rosa Giordano (Ospedale fering with blood pressure regulation: blood volume (BV)Provinciale Civile, Martina Franca); Lorenzo Liberato (Ospedale S.
reduction and an inadequate cardiovascular response [3].Camillo De Lessis, Chieti); Luciano Meschini (Ospedale G.B. Grassi,
Ostia Lido); Luigi Lucani (Ospedale S. Carlo Borromeo, Milano); Carlo Hypovolemia causes an underfilling of the cardiac
Navino (Ospedale Regionale Maggiore della Carita`, Novara); Salvatore chambers, thereby compromising the circulatory load,Mandolfo (Ospedale Provinciale Maggiore, Lodi); and Francesco Bi-
while an insufficient cardiovascular response presup-anco (Ospedale Regionale Maggiore, Trieste).
poses a lack of increase in the arteriolar or venous tone
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not offsetting the volume reduction and favoring theity, blood volume tracking, intradialytic hypotension, end-stage renal
failure. blood pressure decreases [3–5].
A variety of therapeutic maneuvers have been sug-
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sodilating acetate hypotensive effects [7]. Subsequently, METHODS
higher dialysate sodium concentrations and/or use of Ten Italian nephrology centers participated in this pro-
ramped sodium modeling gained widespread currency spective four-month randomized trial. Patients were eli-
[8–11]. Many studies have demonstrated the importance gible for entry to the study if: (a) the thrice-weekly bicar-
of dialysate sodium content in the control of plasma bonate dialysis schedule and treatment time was 180
min; (b) clinical conditions were stable, with a residualrefilling and blood volume changes [8, 10]. A more skilful
diuresis400 mL/day and a stable hemoglobin or hema-use of sodium ramping was, and still is, the use of sodium
tocrit level; and (c) the mean inter-dialytic weight gainkinetic models of varying complexity to establish definite
was 1.5 kg.rules for guiding the choice of the most suitable profile
for a given patient and treatment [9, 12].
Inclusion criteriaOther therapeutic maneuvers for improving cardiovas-
Patients were enrolled for study in the presence of acular stability are the use of a high dialysate calcium con-
reduced hemodynamic tolerance to the dialysis treat-centration, which increases myocardial performance and
ment, defined by at least one episode of acute intradia-leads to a small but statistically significant blood pressure
lytic hypotension in 20 to 80% of the dialysis sessions inincrease [13]. Moreover, cool dialysis has been associated
the two months prior to the start of the study. Moreover,with fewer episodes of hypotension and a significantly
patients had to present at least one of the following co-
higher blood pressure, a consequence of the increase in morbid conditions: cardiac disease, diabetes mellitus I/II,
peripheral vascular resistances [14, 2]. Other therapies and arterial hypertension (already present and diag-
thought to be beneficial in the treatment of intradialytic nosed for at least 6 months). Cardiac disease was consid-
hypotension include alternative dialysis techniques such ered as a previous history of ischemic heart disease or
as hemofiltration or acetate-free biofiltration [15]. the presence of left ventricular hypertrophy. Ischemic
The main drawbacks of profiled dialyses are that they heart disease was a previous history of myocardial in-
are constructed on data from previous clinical observa- farction, coronary artery by-pass surgery or percutane-
tions and not on the response to the changes actually ous transluminal angioplasty or the presence of angina
occurring in the patient during that particular treatment pectoris. Left ventricular (LV) hypertrophy was defined
[16]. An ongoing field of research in dialysis concerns fit- as a LV mass index 131 g/m2 in males and 100 g/m2 in
ting a number of biosensors onto the dialysis circuit to females [19].
Intradialytic hypotension was defined as one of thefeed patient-related information back to (a) the attend-
following three situations: (1) for patients starting theing medical staff who can choose whether or not to
dialysis session with systolic arterial pressure (SAP)change the dialysis prescription, or (b) a special biofeed-
100 mm Hg, a SAP value 90 mm Hg, even in the ab-back unit integrated into the dialysis machine that auto-
sence of any typical low blood pressure symptom; (2) inmatically transmits specific on-line patient status alter-
the case of patients with pre-dialysis SAP 100 mm Hg,ations to the dialysis fluid composition and technical
a SAP reduction of at least 10% of the pre-dialysis value,parameters [17].
accompanied by characteristic symptoms (nausea, vom-Based on a continuous stream of information arriving
iting, sweating, dizziness, yawning); (3) any SAP reduc-on the changes occurring in the circulating blood volume,
tion 25 mm Hg compared to the pre-dialysis value,we have developed a biofeedback system that avoids both
in the presence of the typical symptoms accompanyingsudden excessive falls in BV and consequent side effects,
hypotension, requiring an immediate therapeutic ma-
by way of appropriate on-line adjustments to the weight
neuver (Trendelenburg position, saline infusion, etc.).
loss rate (WLR) and dialysate conductivity (DC) [18].
This system was validated in a pilot study of a small Exclusion criterion
number of non-selected patients, which gave promising The presence of a persistent condition of intradialytic
results in terms of the improvement in cardiovascular blood pressure instability (hypotension episodes in more
treatment tolerance [18]. than 80% of the regular dialysis sessions) was considered
The aim of this work was to compare the blood volume an exclusion criterion, because it probably related to the
tracking system against standard bicarbonate dialysis in particular severity of the clinical conditions, and not only
regard to the improvement of treatment tolerability in to an inadequate cardiovascular tolerance to HD.
a large number of hypotension-prone patients. The sec-
Drop-outondary aim was to identify potentially influential patient
parameters that can help the physician to identify which Criteria for discontinuing the study were: patient re-
patients may draw the most benefits from using continu- fusal, death, intercurrent illnesses, surgery, thrombosis of
the vascular access, or any other reason that caused theous and automatic BV control.
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Fig. 1. Experimental design. The 36 enrolled patients were randomly
assigned to one of the two arms of the study, differing for the sequence
of conventional (A) and blood volume tracking (B) dialysis techniques
(ABAB or BABA, respectively), with each period lasting 4 weeks. At
the end of the follow-up period 32 out of 36 patients were included in
the statistical analysis because of 3 protocol violators and 1 death.
interruption of the study for at least three consecutive Fig. 2. Time course of the blood volume reduction (BV, %), total
sessions. weight loss (WL, kg), dialysate conductivity (DC, mS/cm) and weight
loss rate (WLR, L/h) during a blood volume tracking (BVT) dialysis.All the patients consented to the study, which was
According to the desired time pattern for blood volume and total weightsubmitted to and approved by the Ethical Committees loss (the thin dashed line in 1 and 2), the weight loss rate and dialysate
of the participating Centers. conductivity change time by time to reduce the error between the
desired and observed values. In any case, the WLR and DC are con-
strained within safety limits (dotted lines).Experimental design
All the patients underwent a four-month experimental
period. The study was carried out according to a prospec-
tive, multicenter, crossover, parallel group design, with loss rate and dialysate conductivity were kept constant
two ABAB or BABA sequences as depicted in Figure 1. during the treatment.
In period A the hemodialysis treatment was conventional At each session the body weight loss was set according
dialysis, whereas in period B it was blood volume track- to the difference between the pre-dialysis weight and
ing dialysis (BVT), each period lasting four weeks. After the ideal post-dialysis dry body weight previously defined
a run-in period, the patients were centrally randomized in the run-in period. This target was considered a con-
to one of the two different sequences on the basis of a straint for each session, independently of the patient
balanced block randomization list technique. The pa-
inter-dialysis weight gain.
tients were blinded as to which treatment they were
undergoing. Periods B
During this period the blood-volume controlling tech-Dialysis techniques
nique, described elsewhere [18], was actuated. Briefly,All patients were prescribed bicarbonate-buffered
the dialysis monitor is equipped with an automatic sys-180 to 240 minute HD sessions. The dialysate composi-
tem, a multi-input multi-output controller by which thetion was as follows: sodium 141 mmol/L, potassium 2
measured and controlled variable (BV) is driven towardmmol/L, bicarbonate 32 mmol/L, acetate 3 mmol/L, chlo-
a desired value throughout the session. The actuators,ride 108 mmol/L, calcium 1.75 mmol/L, glucose 1 g/L.
which allow for this control, are the WLR and DC. TheAll the treatments were delivered by dialysis monitors
former acts directly on the BV change, whereas the latterequipped with the blood volume sensor (Hemoscan;
has an indirect effect because it modifies plasma osmolar-Hospal, Bologna, Italy) and with automatic blood vol-
ity and consequently influences the entity of the plasmaume control software, (Hemocontrol; Hospal).
refilling rate. An example of a dialysis session delivered
Periods A using this system is reported in Figure 2. Figure 2 A
and B represent the percentage of blood volume changeDuring these periods conventional HD sessions were
during the session in relation to the desired value (dashedperformed with BV and blood pressure monitoring. The
line) and the actual weight loss, while Figure 2 C and Doperating dialysis variables (dialyzer membrane and sur-
represent the WLR and DC, respectively, which allowface, treatment time, blood and dialysate flow rate, dialy-
the blood volume to get very close to the desired value.sate composition) were the same as the ones already
used in the run-in period. Moreover, both the weight It is worth noting that in any case safety limits must be
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set before starting the dialysis session both for the WLR out the dialysis treatment: (1) body weight, supine and
standing blood pressure and heart rate, before and afterand the DC [18].
The operative variables of the treatment (dialyzer each dialysis session; (2) blood pressure and heart rate
at a 30-minute interval, or more often if necessary; (3)membrane and surface, treatment time, blood and dialy-
sate flow rate, dialysate composition) were kept un- any patient complaints continuously throughout the ses-
sion; (4) pre- and post-dialysis plasma sodium concentra-changed compared to the periods A; the two treatments
were equivalent in terms of dialysate conductivity [18]. tion measured once a week, in the mid-week dialysis
session; (5) once a month, in a mid-week dialysis sessionThe only difference was that both the WLR and DC were
automatically and continuously adjusted throughout the 90 minutes after the dialysis start, evaluation of the vas-
cular access recirculation assessed by the blood ureatreatment by the blood volume controller, in order to
keep the BV changes within the desired time course, as nitrogen (BUN) in the arterial, venous blood stream
and peripheral sample (slow-flow technique) [20]. In thepreviously described.
same session the dialysis dose (Kt/V) also was assessed,
Run-in period based on the Daugirdas second generation formula [20].
Between treatments, symptoms like muscular cramps,Before entering the allotted sequence, each patient
underwent an observational run-in period lasting two headache, dizziness, thirst, dyspnea, angina, vomiting,
itching, the need to lie down, anorexia, asthenia, wereweeks. This period aimed to correct and optimize the
prescription of the ideal post-dialysis body weight and defined as early symptoms if appearing in the first six
hours after the treatment end, or late symptoms if ap-desired value of the BV reduction to be set for treat-
ment B. During this period conventional HD sessions pearing in the following hours until the beginning of the
next dialysis session.were performed with the same characteristics as the usual
patient treatment, with regular BV and blood pressure Blood samples for the evaluation of post-dialysis plasma
sodium concentration were taken from the arterial linemonitoring.
The ideal post-dialysis dry body weight was defined of the extracorporeal circuit at the end of the treatment,
after a two-minute slow flow circulation (50 mL/min).on the basis of both the traditional clinical parameters
(skin and subcutaneous hydration state, jugular vein as-
Sample sizepect, pre-dialysis and intradialytic blood pressure be-
havior, post-dialysis standing blood pressure, intra-treat- The sample size was calculated assuming the mean
percentage difference of acute hypotension episodes be-ment symptoms, such as muscular cramps) as well as the
radiological signs (cardiothoracic index, myocardial di- tween the two treatments as the main response variable.
A significance level of 0.05 ( error) and a power of theameters, pulmonary blood flow distribution, vascular
pedicle aspect) related to the hydration status. Once the test of 0.8 ( error of 0.2) were assumed. We considered
a 15% difference as clinically relevant and a two-tailedideal individual post-dialysis body weight had been de-
fined it was kept unchanged throughout the study, unless paired t test for both errors was used, with a standard
difference of the mean equal to 30%. Hence, the mini-a variation was needed according to the norms of good
clinical practice. mum number of 35 patients resulted. The total number
of patients was not corrected for the drop-out as we hadThe weight-loss normalized BV reduction (BV/WL)
to be prescribed in period B was assessed for each patient expected a very low drop-out rate.
as the average of the recorded ratios of the “end-treat-
Statistical analysisment” BV decrease over the weight loss per session in
the run-in dialyses. The descriptive analysis was carried out for the vari-
ables that identified the main characteristics of the sam-The value of the “end-treatment” BV decrease was
measured either at the very end of the treatment, in ple and the treatments. For these variables data are re-
ported either as mean 	 standard error of the meanthe case of a hypotension-free session, or at the exact
moment of the first hypotension occurrence, before the (SEM) or as occurrences with respect to the whole sam-
ple when appropriate.therapeutic maneuvers, in the case of the appearance of
symptoms. The main statistical analyses were carried out by analy-
sis of variance (ANOVA) for repeated measures on theThe final weight-loss normalized BV reduction (BV/
WL) was considered as the individual patient critical main response variable.
Univariate regression analysis also was performed onthreshold. The prescribed value was a 20% reduction of
the latter. the percentage of acute hypotension episodes in the two
treatments and the Pearson’s r test was assessed. Results
Data collection of the analysis were used to categorize the patients as
high responders or poor responders. More precisely, highDuring both the A and B periods the following clinical,
dialytic and laboratory parameters were assessed through- responder patients were defined as those who during
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Table 2. Number and percentage of patients with only one co-Table 1. Main characteristics of the patients included in the analysis
morbid factor, and with two and three co-morbid factors.
Total ABAB BABA
Total % ABAB BABA
N 32 15 17
Age years 67.1	1.7 65.1	2.9 68.9	2.0 Diabetes 2 6.5
Hypertension 8 25.7Dialysis age months 41.8	5.5 40.0	7.3 43.4	8.4
Sex M/F 14/18 6/9 8/9 Cardiac disease 8 25.7
Total 18 58.1 8 10Dry weight kg 64.8	2.1 65.6	3.1 64.0	2.9
Hemoglobin g/dL 10.3	0.2 10.4	0.3 10.3	0.3 Diabetes  hypertension 4 13.0
Hematocrit % 31.6	0.8 32.0	1.1 31.2	1.2 Diabetes  cardiac disease 1 3.2
Serum albumin g/dL 3.9	0.05 3.9	0.08 3.9	0.08 Hypertension  cardiac disease 6 19.4
Serum total protein g/dL 6.8	0.1 6.7	0.1 6.8	0.1 Total 11 35.4 5 6
Cause of end-stage renal disease
Diabetes  hypertension  cardiac disease 2 6.5 1 1GN 6 (18.8) 2 (14.3) 4 (23.5)
IN 5 (15.6) 2 (14.3) 3 (17.6) The table also reports the distribution of such patients within the two experi-
NAS 8 (25.0) 2 (14.3) 6 (35.3) mental arms.
PKD 6 (18.8) 5 (35.7) 1 (5.9)
D 6 (18.8) 3 (21.4) 3 (17.6)
Values are reported as mean 	 standard error of the mean (SEM) for the
continuous variables and as counts and percentages for categorical variables.
Abbreviations are: GN, glomerulonephritis; IN, interstitial nephropathy; NAS, Table 3. Main characteristics of the treatments delivered
nephroangiosclerosis; PKD, policystic kidney disease; D, diabetes.
A B P value
Dialysis sessions N 789 743 NS
Blood flow mL/min 290	5 291	4 NS
Treatment time min 238	2 238	3 NStreatment A showed a percentage of the acute hypoten-
Pre-set weight loss kg 3.1	0.1 3.1	0.1 NSsion over 30% and presented a high reduction of these
Dialysate conductivity mS/cm 14.2	0.05 14.2	0.03 NS
events during the treatment B, and poor responder pa- Actual weight loss kg 2.7	0.1 2.8	0.1 NS
Pre-HD plasma Na mEq/L 138.7	0.5 138.8	0.6 NStients were classified as those who showed a hypotension
Post-HD plasma Na mEq/L 141.8	0.6 141.3	0.7 NSfrequency over 30% in period A but presented a small
Pre- to post-HD plasma Na
reduction of hypotension episodes during period B (pa- change mEq/L 3.1	0.4 2.5	0.3 NS
Kt/V 
 1.15	0.04 1.11	0.03 NStients positioned between the identity and regression
NS is not significant. Values are reported as mean 	 SEM. The Student t testlines in the scatter plot). For these subgroups of patients
was used to test the null hypothesis for significance.(high and poor responders), multiple logistic regression
analysis was used to identify what clinically relevant vari-
ables may be considered statistically associated with the
incidence of hypotensive events. comorbidity, 35.4% had a double comorbidity, and two
All the statistical analyses were made using SPSS 9.0 patients (6.5%) presented all three conditions listed in
package for Windows (SPSS Inc., Chicago, IL, USA). the inclusion criteria (Table 2).
Patients received a comparable dialysis treatment both
in conventional as well as in BVT dialysis (Table 3). TheRESULTS
blood flow rate was 290 	 5 mL/min in period A andAt the end of the enrollment period, 36 patients had
291 	 4 mL/min in period B, the length of dialysis wasentered the study from ten dialysis units. Three patients
238 	 2 min (A) versus 238 	 3 min (B), and the pre-were protocol violators because a wrong sequence was
set weight loss (3.1 	 0.1 kg both in A and B) and theinitiated and one patient was dropped due to death. As
actual loss (2.7 	 0.1 kg in A vs. 2.8 	 0.1 kg in B)a consequence, four patients were not assessable, and
were comparable. As a further check of the delivered32 were included in the statistical analysis (Fig. 1).
treatment the dialysis dose (Kt/V) was similar for theTable 1 illustrates the main clinical characteristics
two periods (1.15 	 0.04 in A vs. 1.11 	 0.03 in B, di-(age, dialytic age, hemoglobin, serum albumin and total
mensionless). Regarding the electrolyte balance, againproteins, underlying nephropathies) of these patients.
the two treatments were comparable. In fact, the patientsAt the end of the randomization process, the distribu-
showed an equivalent plasma sodium variation duringtion of the patients within the two experimental arms
the treatments (pre- to post-dialysis sodium change waswas well balanced (Table 1) in terms of the patient pa-
3.1 	 0.4 mEq/L in A and 2.5 	 0.3 mEq/L in B) start-rameters described above, with no biases except for the
ing with the same pre-dialysis plasma sodium contentunderlying nephropathies, which showed a higher num-
(138.7 	 0.5 mEq/L in A vs. 138.8 	 0.6 mEq/L in B)ber of patients affected by nephroangiosclerosis assigned
for a comparable weight loss (Table 3).to sequence 2 (6 vs. 2) and patients affected by polycystic
From the cardiovascular point of view (Fig. 3, top), akidney disease assigned to sequence 1 (5 vs. 2).
better treatment tolerance could be achieved during BThe enrolled patients presented with differing degrees
of disease severity: 58.1% presented a single cause of periods compared to A. On average, a significant reduc-
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Fig. 3. Hypotension during dialysis (top) and
symptoms during the inter-dialysis period (bot-
tom). The frequency of dialysis hypotension
is reported as a whole (left; *) and within each
sequence. The latter also reports the frequency
during the run-in period, here indicated as
the first A period before each sequence. The
analysis neglecting the sequence showed a sta-
tistically significant reduction in the hypo-
tension event rate (P  0.004). The average
number of symptoms occurring during inter-
dialysis is reported as early (**) when it oc-
curred in the first 6 hours after the end of
dialysis, or as late (‡) when occurring between
this time and the start of the following dialysis
session. All the values are statistically signifi-
cant at 1‰ level (P  0.001).
tion in hypotensive events was observed: the percentage dialysis tolerance throughout the inter-dialysis period
with a significant reduction of symptoms when changingof dialysis sessions complicated by acute hypotension
events was 33.5% in A and 23.5% in B (30% less in B from treatment A to B (10% decrease, P  0.001).
The individual hypotension event rate for each patientthan in A, P  0.004). This decrease in the event rate
was more marked in the ABAB sequence than in the is reported in the scatter plot in Figure 4, where the
horizontal axis reports the hypotension frequency in con-other one, although the experimental arm (assumed to
be covariate) did not affect the variability between the ventional dialysis and the vertical axis the hypotension
frequency in BVT dialysis. The figure also shows thetwo groups in the analysis of variance. In fact, in the
ABAB arm the hypotension events decreased from 34 regression line and the confidence limits at 95% level of
the mean; the identity line is shown for comparison. Theto 20% and from 29 to 17% by changing from the A to the
B periods. In the BABA sequence they did not change in latter states the boundary limit when the two treatments
behave equally. Indeed, the regression line presents athe first step (31% of hypotension events in the first B
period vs. 30% in the first A period), while in the second slope lower than 1 showing a general improvement with
respect to the treatment tolerance by moving from con-step a larger increase was observed by changing from
the second B period to the second A period (from 28 to ventional to BVT dialysis. The 95% confidence interval
for the regression line slope ranges from 0.33 to 0.75. In39% of hypotension events).
Similar findings were obtained for the inter-treatment fact, most of the patients lie in the region below the
identity line. The results reported in the scatter plot ofsymptoms. At the bottom of Figure 3, the average num-
ber of symptoms between two consecutive sessions are Figure 4 are highlighted in Figure 5, which shows the per-
centiles and 95% confidence interval of the differenceshown either within the first six hours from the end of
dialysis (early symptoms) and later until the beginning of of the hypotension frequency in the two treatments (B
minus A) in relation to the different blood pressure sta-successive dialysis sessions (late symptoms). The average
number of symptoms over the whole inter-dialysis period bility in A. Patients were subgrouped according to per-
centiles of hypotension frequency during the period A.also is reported. We noted that there was a better post-
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Fig. 4. Individual frequency of the symptom-
atic intradialytic hypotension episodes during
dialysis in blood volume tracking (BVT; B
period) plotted against the frequency of the
intradialytic hypotension episodes in conven-
tional dialysis (A period). The scatter plot also
shows the identity, the regression line (thick
solid line; y  0.54 x  5; r  0.4, P  0.001,
95% confidence interval for the slope ranging
from 0.33 to 0.75) and the confidence limits
of the mean at 95% level. Finally, the region
at the right of 30% of hypotension episodes
in the A period defines the highly critical pa-
tients.
the supine as well as in the standing positions. Also, the
end-dialysis blood volume reductions showed compara-
ble results.
It is worth noting in Figure 4 that the more critical
the patients were in terms of cardiovascular stability
during dialysis, the greater the benefits obtained by
applying BVT. The scatter plot suggested focusing on the
particularly critical patients who showed a hypotension
frequency higher than 20%. Almost all the patients were
located in the region below the identity line, while a
group (7 out of 14) seemed to benefit favorably from
BVT. This subgroup located in the region below the re-
gression line was classified as high responder, and the sub-
group in the region between the regression and the iden-
tity lines was classified as poor responder.
Further analysis was restricted to these sub-groups inFig. 5. Percentiles and confidence intervals at 95% of the distributions
of the difference between the frequency of hypotension in B minus A an attempt to find some patient parameters that could
treatments plotted against the percentiles of the frequency of hypoten- identify the patients a priori as high or poor responders.
sion in conventional dialysis (A treatment).
High and poor responder patients did not differ with
regard to the clinical parameters (Table 5). In fact, age
was comparable (67.4 	 10.6 years for high responders
and 66.3 	 7.7 years for poor responders), as well asIt can be seen that patients belonging to the group with
time on dialysis (32.2 	 29.9 months in high respondersfewer hypotension episodes in conventional dialysis (treat-
vs. 50.3	 38.3 months for poor responders), hemoglobinment A) do not seem to benefit from the BVT system
(10.7 	 0.8 g/dL vs. 10.5 	 1.2 g/dL), serum albumin(median 
0.333%), which, instead, proves itself to be
(3.9 	 0.2 g/dL vs. 4.0 	 0.4 g/dL) and total serummuch stronger when the patients are more critical, that
protein concentration (6.7 	 0.2 g/dL vs. 7.0 	 0.2 g/dL,is, in those with a higher number of hypotension episodes
respectively). These subgroups underwent similar dial-when on conventional dialysis. In fact, for those over the
ysis treatments in both periods (A and B). In fact, the25% threshold of hypotension episodes in conventional
dialysis, most of the patients (median values) present a treatment time was similar (around 230 min for high
responders and slightly higher, about 240 min, for poornearly 20% reduction.
From the cardiovascular point of view there was no responders) as well as the blood flow rate (300 mL/
min for both the groups and the treatments). Moreover,appreciable difference between the two treatments (Ta-
ble 4). In fact, over the whole sample, arterial pressure the actual weight loss did not differ in the two groups
of patients albeit with different behaviors (even if notand heart rate were comparable with the patient in both
Santoro et al: Blood volume controlled hemodialysis 1041
Table 4. Cardiovascular parameters recorded in A and B periods of the study
Position A B P value
End-dialysis BV reduction % 
9.6	0.7 
9.4	0.6 NS
Arterial pressure mm Hg Standing pre- 151/82	4/3 151/82	4/3 NS
post- 123/72	4/3 122/71	4/3 NS
Heart rate beats/min Standing pre- 81	2 81	2 NS
post- 92	3 91	3 NS
Arterial pressure mm Hg Supine pre- 149/79	4/2 149/78	4/2 NS
post- 135/74	3/2 133/74	3/2 NS
Heart rate beats/min Supine pre- 75	2 75	2 NS
post- 79	2 79	2 NS
Arterial pressure is reported as systolic/diastolic. Data are reported as mean 	 SEM. The Student t-test was used to test the null hypothesis for significance.
Table 5. Patients and treatment-related characteristics for the two subgroups (high and poor responders)
High responders Poor responders
N 7 7
Age years 67.4	10.6 66.3	7.7
Dialysis age months 32.3	29.9 50.3	38.8
Sex M/F 3/4 1/6
Hemoglobin g/dL 10.7	0.8 10.5	1.2
Hematocrit % 33.5	3.3 32.5	3.4
Serum albumin g/dL 3.9	0.2 4.0	0.4
Serum total protein g/dL 6.7	0.2 7.0	0.2
A B A B
Blood flow mL/min 296	4 286	10 298	2 295	5
Treatment time min 233	18 232	21 239	21 239	21
Actual weight loss kg 3.14	0.9 3.15	0.9 2.9	0.6 3.3	0.9
Post HD body weight kg 60.7	10.9 61.2	12.2 64.8	9.5 64.6	9.0
Pre HD plasma Na mEq/L 140.3	3.0 141.2	2.6 137.4	3.8 137.5	3.8
Post HD plasma Na mEq/L 144.6	3.8 144.5	3.7 140.7	3.1 139.8	5.0
Kt/V 1.3	0.3 1.4	0.2
Data are reported as mean 	 SEM.
statistically significant). In fact, the high responders statistical significance. Moreover, the BV reduction at
achieved a post-dialysis weight in BVT treatment 0.5 kg the collapse time is similar to the one recorded at the end
higher than in the conventional dialysis at the same total of dialysis for both the subgroups as well as for the
weight loss. The poor responders achieved a lower post- treatments. Finally, the end dialysis blood volume reduc-
dialysis weight with the BVT treatment than with con- tion is slightly greater in conventional dialysis than in the
ventional dialysis (
0.2 kg), but corresponding to a BVT treatment both in the high and the poor responders.
higher total weight loss during this period than in conven- These results could be summarized by the BV/WL
tional dialysis (2.9 vs. 3.3 kg in conventional and BVT ratio, which was lower in the high responder patients in
treatments, respectively). both of the treatments.
In high responder patients both pre- and post-dialysis The mean standing arterial pressure was generally
plasma sodium values were slightly higher (3 mEq/L higher in the high responders by about 17 mm Hg com-
difference) than in the poor responders in concomitance
pared to the poor responders, both in conventional and
with a lower post-dialysis weight. This result was not
BVT dialysis. The pre- to post-dialysis mean blood pres-statistically significant, nor was the pre- to post-dialysis
sure difference increased up to 20 mm Hg between theplasma change. Hence, it seems that BVT does not shift
high and poor responders. The pre-dialysis blood pres-the pre- and post-dialysis plasma sodium.
sure difference between the two groups increased as theThe analysis of the cardiovascular parameters (Ta-
patient’s position changed from standing to lying, upble 6) showed that despite a similar total weight loss
to 24 mm Hg, while it tended to decrease by the end(Table 5), the blood volume reduction at the end of
of the treatment (11 mm Hg). The high responder pa-both the treatments (A and B) was greater in the high
tients showed a slightly higher sensitivity to the posturalresponder patients (
12.7 	 1.7% in A, 
11.6 	 1.5%
change than the poor responders. In fact, the first groupin B) than in the poor responders (9.8 	 1.0% in A,

9.6	 1.0% in B), although this difference did not reach experienced a mean blood pressure decrease of about
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Table 6. Cardiovascular parameters recorded in the two periods of the study referred to the two subgroups of patients
High responder Poor responder
Position A B A B
End dialysis BV % 
12.7	1.7 
11.6	1.5 
9.8	1.0 
9.6	1.0
BV at the collapse time 
12.5	1.5 
11.8	1.4 
8.3	1.3 
9.6	1.3
BV/WL %/kg 
4.1	0.4 
3.8	0.4 
3.1	0.7 
3.1	0.6
MAP mm Hg Standing pre- 114	4a 113	4a 97	5a 96	3a
post- 92	5a 94	4a 75	3a 74	2a
HR beats/min Standing pre- 82	4 81	5 82	5 82	3
post- 101	6 102	7 93	4 93	4
MAP mm Hg Supine pre- 109	3a 108	3a 85	3a 84	3a
post- 96	3a 98	4a 85	3a 84	3a
HR beats/min Supine pre- 74	4 72	4 75	3 76	3
post- 85	4 84	4 80	3 79	3
Hypotension frequency % 60.5	5.4 24.2	3.7 57.3	4.7 52.9	5.6
Data are the blood volume reduction (BV) at the end of dialysis and at the time of hypotension, the ratio between the latter and the actual weight loss (WL),
mean arterial pressure (MAP) and heart rate (HR). Data are reported as mean 	 SEM. The ANOVA test was applied assuming the responsiveness (high and poor
responder) and the treatment (A and B) as factors.
a P  0.05 between groups effect for the factor responsiveness
15 mm Hg when changing position, while the second significance either in patient responsiveness or dialysis
techniques (high vs. poor responders, P  0.506; A vs.group showed a pressure reduction of 12 mm Hg.
B, P  0.94).Finally, the ANOVA test showed a significant differ-
The higher value of mean arterial pressure in the highence between the groups at the 5% level.
responders with respect to the poor responders paved theThe high and poor responder patients presented a
way for a further investigation into the likely prognosticsimilar pre-dialysis heart rate both in the standing and
factors that can identify the two subgroups. For this pur-supine positions, as well as in the A and B treatments.
pose a binary logistic regression analysis was performedThe heart rate tended to increase toward the end of di-
assuming the high and poor responder classification asalysis by about 10 beats/min in the supine position in
the dependent variable. The factors included were pre-the two groups as well as in the two treatments. Indeed,
to post-heart rate changes in A and B treatments, thethe high responder patients showed a marked rise in the
blood volume reduction at the collapse time in both thestanding heart rate (20 beats/min) in A and B treatments
treatments, the pre-dialysis standing and supine systolicthat was not seen in the poor responders, where the
arterial pressures, and the pre-dialysis plasma sodiumstanding heart rate increase was of the same magnitude
level. The parameter estimates of logistic regression co-as when they were in the supine position (10 beats/min).
efficients are reported in Table 7. The table also reportsThe differences in the systolic arterial pressure and
the result of the test on the null hypothesis of no differ-heart rate at the beginning and at the end of dialysis in
ence for the regression coefficients using the Wald statis-the two subgroups were found throughout the dialysis.
tics. The only covariate that seemed to significantly pre-Figure 6 shows systolic pressure and heart rate recorded
dict a patient as a high or poor responder was his/herevery 30 minutes during the dialysis session. Despite sim-
supine pre-dialysis systolic arterial pressure (P  0.04).ilar pressure patterns, the high responders showed higher
The higher the value of this pressure, the more likely itvalues than poor responders. Blood pressure decreased
is that the patient would favorably benefit from the BVTduring dialysis, achieving the minimum value after 210
treatment.minutes (127	 7 mm Hg for the high responders, 105 	
The difference in the blood volume reduction between4 mm Hg for the poor responders in A; 137 	 9 mm Hg
the two subgroups at the collapse time was at the limitfor the high responders, 105	 3 for the poor responders
of the statistical significance (P  0.08) and could notin B). The ANOVA test for repeated measures revealed
guarantee patient classification.a statistical significance for the patient responsiveness
(high vs. poor responders, P  0.001) but not for the
DISCUSSIONtreatment (A vs. B, P  0.800).
Heart rate (Fig. 6, bottom) rose until 210 minutes after This work demonstrates that by means of the continu-
the start of dialysis, achieving the maximum value there ous and automatic control of blood volume, it is possible
(90 	 6 beats/min in A vs. 90 	 7 beats/min in B for the to reduce the incidence of hypotension during hemodial-
high responders; 84 	 4 beats/min in A vs. 85 	 3 beats/ ysis in patients suffering from this disorder. These data
min in B for the poor responders). Afterwards, it dropped are consistent with the previously published results rela-
until the end of the treatment periods. The ANOVA tive to the use of biofeedback HD in hypotension-prone
patients [18, 21].test for repeated measures did not show a statistical
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Fig. 6. Time course of systolic arterial pressure (A) and heart rate (B) in the high and poor responder patients. The table below the figure reports
the significance of the main factors and interaction terms for the ANOVA for repeated measures model. As concerns systolic arterial pressure,
the test revealed a statistical significance between subjects (high and poor responders, P  0.001). Treatment (A or B) did not seem to influence
either systolic pressure or heart rate (P  0.8 and P  0.94, respectively).
Table 7. Logistic regression analysis observation that when blood volume fell below the
threshold of 50 mL/kg in their patients arterial hypoten-95% Confidence
interval sion appeared [22]. Afterwards, first Maeda, Morita andOdds P
ratio Lower Upper value Shinzato [23], and then Krepel et al [24] contested this
claim because they were unable to demonstrate a closePre- to post-dialysis HR change in A 1.02 0.95 1.10 0.52
Pre- to post-dialysis HR change in B 1.04 0.96 1.13 0.30 relationship and a temporal overlap between the maxi-
Symptomatic BV in A 1.45 0.96 2.21 0.08 mum reduction of BV and the reductions in arterialSymptomatic BV in B 1.26 0.88 1.78 0.20
pressure. In fact, there is no linear relationship betweenPre-dialysis supine SAP 1.10 1.01 1.21 0.04
Pre-dialysis standing SAP 1.12 0.98 1.28 0.10 the BV variations and those in BP. Between these two
Pre-dialysis Na 1.36 0.90 2.03 0.14 variables the cardiovascular response to hypovolemia is
The model took into account the main effect of the predictive variables. inserted [3], which, by means of increases in myocardialAbbreviations are: HR, heart rate; BV, blood volume; SAP, systolic arterial
pressure. contractility, heart rate, arteriolar and venous vasocon-
striction, is able to offset the blood pressure reduc-
tions induced by a wide range of hypovolemic states [25].
During dialysis, however, the cardiovascular system isThe present study demonstrates that the most symp-
submitted to continuous stresses deriving from a con-tomatic patients and those with the highest frequency of
stant state of hypovolemia, which in some moments ofhypotension episodes appear to benefit most from the
the dialysis session undergoes further sudden variations,automatic BV control. This fact, seen from the patho-
owing to the temporary failures of the plasma refilling.physiological perspective, indicates that hypovolemia is
This state of continuous activation together with the inter-not only the primum movens in the chain of events lead-
ference of destabilizing and vasodilating factors such asing to the arterial pressure drops during dialysis, but is
thermal stress [14], nitric oxide [26] and the prostaglan-one that has its own true and proper causal role. The
dins [3], leads to critical situations of disequilibrium giv-importance of hypovolemia in the genesis of IDH had
been put forward by Kim et al in 1970 following the ing rise to sudden BP reductions [27]. The automatic
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control can prevent major hypovolemic variations [13], patients who have refilling problems and who have im-
portant intradialytic hypovolemia episodes. Contrarily,and acts as a buffer to all the sudden variations that may
occur during the hemodialysis treatment. The cardiocir- patients with a good plasma refilling but important car-
diomyopathies, as the poor responders probably have,culatory system is thus submitted to less stress and can
best perform its function as a sentinel in regard to hypo- may well draw fewer benefits from the continuous use
of BVT.volemia consequent to ultrafiltration.
In practice, everything becomes more physiological, This work has shown the advantages of BVT with
regards to symptoms such as asthenia, headaches, nauseaas indeed the essence of physiology is regulation [28].
The human body has thousands of control systems inter- and vomiting that appear in the post-dialysis period; even
these, as in the case of arterial hypotension, are signifi-acting with one another, whose main aim it is to keep
the internal environment under such constant conditions cantly reduced in the B periods compared with the A
periods. It is not easy to give a clear explanation for thisas are compatible with cell life. Most of these control
systems have the main characteristic of performing their result. In fact, in the two types of treatment (A and B)
the dialysis efficiency measured with the Kt/V was identi-action by a negative feedback consisting of a series of
changes that return the deviating factor toward its nomi- cal and the increments in the sodium concentration were
the same at the end of the treatments, as were the totalnal value [29]. The BVT system behaves in the same
way with regard to BV variations. For a feedback system weight losses. In the B treatments there was a lower de-
gree of hypovolemia, but this difference was not actuallyto work, however, there has to be a certain degree of re-
activity and a capacity on the part of the organism itself statistically significant. A possible explanation could be that
the BVT system ensures a greater equilibrium through-to implement a series of measures aimed at contrasting
the negative effects that the control system can minimize out the dialysis treatment and submits the organism to
less critical situations both in terms of refilling and pres-though not completely attenuate. Indeed, the patients
who benefit most from BVT are those who have the sure. This results in a greater energy saving, which trans-
lates into fewer symptoms in the post-dialysis phase.highest pressure values at the start of the treatment and
have the highest increases in heart rate when moving Regarding the reduction of the hypotensive episodes
observed in period B, there seems to be a certain se-from the lying to the standing position. On the other
hand, patients with reduced blood pressure values (MAP quence effect. As a matter of fact, the results seem to be
better in the ABAB sequence compared with the BABA100 mm Hg) at the start of the treatment seem to
respond much less well. Low blood pressure values in sequence. There are two possible explanations for this phe-
nomenon. A certain carry-over effect may exist, whichhemodialysis are often indicative of the existence of car-
diomyopathies with a compromised systolic function ac- means that the benefits in terms of the intradialytic hypo-
tension prevention are prolonged in period A even be-companying a greater morbidity and mortality [30]. Un-
fortunately, one of our study’s limitations is that, as serial yond the end of the preceding B period. Moreover, this
phenomenon also occurs with dialysis techniques differ-echocardiography and Doppler were not performed, we
are unsure whether the low BP observed in the poor ent from traditional hemodialysis, such as hemofiltration,
which maintains a certain degree of protection with re-responder patients was due to a low cardiac output or to
a decrease in peripheral resistances. The poor responder gard to the hypotensive phenomena when it is prolonged
for a certain period. The other possible explanation ispatients have a lower increase in their heart rate after
standing and this could be the expression of an auto- that in the BABA sequence, a greater number of patients
had vascular pathologies (there were 6 patients withnomic nervous system dysfunction both in terms of the
sympathetic efference and the baroreceptor per se. nephroangiosclerosis out of 17, compared with 2 in the
ABAB sequence). Those with more serious clinical con-Another factor that seems to identify the high re-
sponder patients is the hypovolemic variations both at ditions of vascular deficiency could offset the benefits of
the BVT treatment in preventing arterial hypotension.the end of the treatment and at the collapse moment.
Both of these BV variations are higher in the high re- In conclusion, by applying BVT to patients with intra-
dialytic cardiovascular instability, we observed a signifi-sponders compared with the poor responders, with a
difference of more than 3%. Unfortunately, the differ- cantly lower incidence in hypotensive episodes and a
reduction in the frequency of symptoms during the inter-ence is not significant from the statistical point of view,
probably as a result of the low number of cases. This dialytic period. This would be the first step toward a
“physiological dialysis” where the dialysis treatment pa-fact, together with the greater BV/WL ratio observed in
the high responder patients indicates a certain plasma rameters, such as the weight loss rate, dialysate conduc-
tivity, dialysate temperature and many others, are notrefilling pathology. Indeed, these patients, compared
with the poor responders, present a lower vascular refill- pre-set by the technician but are dynamically changed
by a dialysis delivery system incorporating adaptive anding, ultrafiltration being equal. The BVT is thus more
effective in preventing hypotension during dialysis in logic controls.
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